What is Verge Genomics?
Founded in 2015 and headquartered in California, Verge Genomics operates at the intersection of artificial intelligence and human biology. The company utilizes a unique, data-driven approach to identify novel therapeutic targets, aiming to reduce the high failure rates typically associated with traditional drug development. By integrating large-scale genomic datasets with machine learning, Verge Genomics is effectively shortening the timeline for bringing life-saving treatments to market, positioning itself as a critical player in the next generation of precision medicine.
How much funding has Verge Genomics raised?
Verge Genomics has raised a total of $134.3M across 4 funding rounds:
Angel/Seed
$4M
Series A
$32M
Debt
$350K
Series B
$98M
Angel/Seed (2015): $4M with participation from Lerer Ventures, Two Sigma Ventures, Draper Associates, Great Oaks VC, Karlin Ventures, and Slow Ventures
Series A (2018): $32M led by DFJ
Debt (2020): $350K supported by PPP
Series B (2021): $98M featuring Merck Global Health Innovation Fund, BlackRock, Section 32, Vulcan, and Lilly
Key Investors in Verge Genomics
DFJ
Draper Fisher Jurvetson is a prominent venture capital firm with a global footprint, dedicated to providing capital and strategic support to entrepreneurs building industry-changing companies.
BlackRock
BlackRock is a world-leading investment management firm that provides institutional clients with comprehensive risk management and capital allocation services across diverse asset classes.
Section 32
Section 32 is a venture capital firm founded by Bill Maris that focuses on investing in cutting-edge technology and supporting visionary entrepreneurs at the forefront of scientific advancement.
What's next for Verge Genomics?
With the infusion of capital from its latest financing round, Verge Genomics is well-positioned to accelerate its pipeline development and expand its internal research capabilities. The company is expected to focus on scaling its AI-driven discovery engine to address complex neurological and immunological conditions. As it moves into this next phase of growth, the firm will likely prioritize strategic partnerships with global pharmaceutical entities to validate its platform's efficacy in clinical settings, ultimately aiming to transform the standard of care for patients with high unmet medical needs.
See full Verge Genomics company page
